About: Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article by Ernest Choy et al published 2019 in RMD open

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2019 (fr) наукова стаття, опублікована у 2019 (uk) im Januar 2019 veröffentlichter wissenschaftlicher Artikel (de) scholarly article by Ernest Choy et al published 2019 in RMD open (en)
publication date	wds:Q64235103-68EDE4A5-EB71-4AA3-9E1B-F0BD6FCCCB5B
publication date	2019-01-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q64235103-F82C3A62-E6F9-4323-B54F-4B82077CDF5E
language of work or name	English
cites work	wds:Q64235103-092DC8CB-C019-4FBB-80CD-237E21497AA7 wds:Q64235103-0B9D4A1B-D5A3-4C00-BA98-A23DACF855AC wds:Q64235103-1325B89E-F863-44C7-BB32-82DCE6802D0C wds:Q64235103-146BC894-D5DC-40CC-BA22-1D550FB77B65 wds:Q64235103-1560BD0A-B1D0-4BAB-87AF-86879AAA4A4B wds:Q64235103-22A8E4DF-AE43-4CC4-AEE0-92B12411F856 wds:Q64235103-244B6783-2981-4800-8EB9-BCEA4C61E2FC wds:Q64235103-27B8E3B2-5DB4-4520-911B-EAB2DD7C9383 wds:Q64235103-28BA99F8-6777-4861-822E-1A1BD65CCFB3 wds:Q64235103-31474764-F9A3-427D-9260-D3E65D24075F wds:Q64235103-3DE26E87-79E0-4D47-AE69-D577B1AA04EB wds:Q64235103-47D14F72-8556-4583-A1CD-035122C7BA0F wds:Q64235103-496DD966-0170-47E2-A600-2B658C55A653 wds:Q64235103-562DFAA9-9773-4BD7-96EE-F329553C60A9 wds:Q64235103-621FCE7D-2DE6-43CD-B185-CF1FF6DE3DEF wds:Q64235103-62CB0F60-9D4B-4CD3-905E-E05D2F9DAE16 wds:Q64235103-6BC5BD2D-6AF0-4ABA-981D-DEE8902E9600 wds:Q64235103-6F9C84C2-14C9-47B6-B079-F2A78ED98FE5 wds:Q64235103-726A2D9D-1B44-4E07-9DF0-6E106695AE0C wds:Q64235103-729EDFD6-3952-429B-BD56-680712B0FB72 wds:Q64235103-72A1A070-F276-4C7E-B352-952AEA2C4F72 wds:Q64235103-7CD92642-7826-4031-9AF7-B64E70AE1D76 wds:Q64235103-8F4C4666-1DDA-4695-9E08-DB014C02EADB wds:Q64235103-BCA489F9-D954-4A71-B672-0B41BFBC6320 wds:Q64235103-BF30A9F3-9E46-44F3-BA4A-A56C981E2CD5 wds:Q64235103-BFFB7B47-0165-45EF-9A2A-FC1BD4BF8EB8 wds:Q64235103-C4AF1D59-D002-4BB5-BE4A-B16F8E674347 wds:Q64235103-DC4F2312-4985-4BE8-9575-611B8CB0F3C7 wds:Q64235103-DF8BD8BF-D0B8-48DD-84C2-D2DD6C97D344 wds:Q64235103-DFD2080A-4ACA-4156-AE7F-7B7BEC908883 wds:Q64235103-EBD5D03D-C4DE-41FD-B93E-86A888846C34 wds:Q64235103-F0A5215C-259A-4958-97FE-4776CF912C8E wds:Q64235103-F44520D6-5477-4711-A341-D8432123714B wds:Q64235103-FDD2D822-8227-4982-8148-09E4FD9F6CCE
cites work	Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study Combination of direct and indirect evidence in mixed treatment comparisons Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Evidence synthesis for decision making 3: heterogeneity--subgroups, meta-regression, bias, and bias-adjustment Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial Indirect comparisons of therapeutic interventions Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont Effectiveness of TNF inhibitor treatment with various methotrexate doses in patients with rheumatoid arthritis: results from clinical practice The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study Bayesian approaches to random-effects meta-analysis: a comparative study. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison Indirect Comparisons and Network Meta-Analyses Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study Evidence of comparative efficacy should have a formal role in European drug approvals Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
author name string	wds:Q64235103-147427AF-5B6B-4693-8B6A-EBD5865E6D4F wds:Q64235103-17984A4B-C237-40D1-AAFA-5A932A857DDB wds:Q64235103-2AD77C05-3690-46A1-A2E6-9BDC2DA4BE0A wds:Q64235103-4B46BB79-582D-46C3-80C7-3182B70ED938 wds:Q64235103-649D467A-FA24-471D-B1E7-86A5A5C59A2D wds:Q64235103-90412F84-1415-44AA-856C-AF1B64CF6DF7 wds:Q64235103-B5976678-E1CA-4AFD-98D1-249F2F454C6B wds:Q64235103-CD143005-CC80-4A2B-891F-A0D8CA4F8F7A wds:Q64235103-D889AD42-1CC8-448A-A842-7BEB00D9A228 wds:Q64235103-F1253BE7-F00D-4916-8A00-A639585E9832
author name string	Nick Freemantle Andreas Kuznik Ernest Choy Chieh-I Chen Erin Mangan Paulo Carita Clare Proudfoot Hubert Van Hoogstraten Laurence Pollissard Thi-Minh-Thao Huynh
rdfs:label	Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature (en) Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature (nl)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software